CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today congratulates Robert S. Langer, ScD, InVivo co-founder and member of the Company’s scientific advisory board, on receiving the National Medal of Technology and Innovation. President Barack Obama will present the award to Dr. Langer, who also won the National Medal of Science in 2006, at a White House ceremony in early 2013.
Dr. Langer, the David H. Koch Institute Professor at the Massachusetts Institute of Technology (MIT), is among 23 renowned researchers who have been awarded the nation’s highest honors for scientists, engineers, and inventors this year. With this award, he joins the ranks of five engineers and inventors from MIT who have earned the same honor, and becomes one of three Americans to have won both the National Medal of Science and the National Medal of Technology and Innovation.
“The impact of Bob’s biomaterials research and drug/cell delivery innovations are enormous, and his discoveries have now led to over 55 products either currently in clinical trials or already approved by the FDA,” said InVivo Chief Executive Officer Frank Reynolds. “The range of Bob’s humanitarian impact is only exceeded by his dedication to help people with ‘tough to solve’ unmet medical needs. InVivo is fortunate to benefit from many of his patents and as we look forward to beginning clinical studies in early 2013, our team couldn’t be happier to see Bob recognized by President Obama for his major contributions to the worlds of biomaterials, tissue engineering, tissue regeneration and drug delivery.”
For more on the National Medical of Technology and Innovation please visit http://www.whitehouse.gov/the-press-office/2012/12/21/president-obama-honors-nation-s-top-scientists-and-innovators.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who is affiliated with Massachusetts General Hospital.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to sell additional shares of common stock and warrants to purchase common stock at additional closings, the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 10-K, Form 10-Q and Form 8-K. We do not undertake to update these forward-looking statements made by us.